Equities research analysts forecast that Agios Pharmaceuticals Inc (NASDAQ:AGIO) will post $22.05 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Agios Pharmaceuticals’ earnings. The lowest sales estimate is $19.50 million and the highest is $24.60 million. Agios Pharmaceuticals reported sales of $8.76 million during the same quarter last year, which indicates a positive year over year growth rate of 151.7%. The business is expected to report its next earnings report on Friday, May 3rd.
According to Zacks, analysts expect that Agios Pharmaceuticals will report full year sales of $109.76 million for the current financial year, with estimates ranging from $77.08 million to $143.10 million. For the next year, analysts anticipate that the firm will report sales of $154.28 million, with estimates ranging from $114.00 million to $187.30 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Agios Pharmaceuticals.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, February 14th. The biopharmaceutical company reported ($1.58) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.65) by $0.07. The business had revenue of $30.00 million during the quarter, compared to analyst estimates of $19.98 million. Agios Pharmaceuticals had a negative net margin of 366.61% and a negative return on equity of 44.13%. Agios Pharmaceuticals’s revenue for the quarter was up 200.0% compared to the same quarter last year. During the same quarter last year, the business posted ($1.81) earnings per share.
In other Agios Pharmaceuticals news, insider Scott Biller sold 9,000 shares of Agios Pharmaceuticals stock in a transaction on Wednesday, February 27th. The shares were sold at an average price of $65.00, for a total transaction of $585,000.00. Following the completion of the sale, the insider now owns 28,277 shares of the company’s stock, valued at approximately $1,838,005. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Steven L. Hoerter sold 10,000 shares of Agios Pharmaceuticals stock in a transaction on Monday, March 4th. The stock was sold at an average price of $67.01, for a total transaction of $670,100.00. Following the sale, the insider now directly owns 26,939 shares of the company’s stock, valued at approximately $1,805,182.39. The disclosure for this sale can be found here. 3.02% of the stock is currently owned by insiders.
Several hedge funds have recently made changes to their positions in AGIO. Bank of New York Mellon Corp grew its holdings in shares of Agios Pharmaceuticals by 3.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 212,733 shares of the biopharmaceutical company’s stock valued at $17,918,000 after buying an additional 6,169 shares during the period. Rockefeller Capital Management L.P. acquired a new position in shares of Agios Pharmaceuticals in the 3rd quarter valued at $134,000. Cannell Peter B & Co. Inc. acquired a new position in shares of Agios Pharmaceuticals in the 3rd quarter valued at $3,739,000. MML Investors Services LLC acquired a new position in shares of Agios Pharmaceuticals in the 3rd quarter valued at $255,000. Finally, Piedmont Investment Advisors Inc. grew its holdings in shares of Agios Pharmaceuticals by 342,300.0% in the 3rd quarter. Piedmont Investment Advisors Inc. now owns 3,424 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 3,423 shares during the period. 98.19% of the stock is owned by institutional investors.
Shares of Agios Pharmaceuticals stock traded down $2.41 during midday trading on Friday, reaching $63.51. The company had a trading volume of 405,700 shares, compared to its average volume of 491,926. The firm has a market cap of $3.85 billion, a P/E ratio of -10.53 and a beta of 2.38. Agios Pharmaceuticals has a 1-year low of $41.63 and a 1-year high of $99.82.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Further Reading: What is a balanced fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.